Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b study of neoadjuvant RBP-01 in primary uveal melanoma
MOH_2026-09-27_017054Phase 2Not yet recruiting
- Sponsor
- ReBio Technologies
- Start
- Sep 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RBP-01 in intraocular melanoma, sponsored by ReBio Technologies. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RBP-01
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on MOH_2026-09-27_017054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-27_017054.